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Most Listeria monocytogenes virulence genes are positively regulated by the PrfA protein, a transcription
factor sharing sequence similarities with cyclic AMP (cAMP) receptor protein (CRP). Its coding gene, prfA, is
regulated by PrfA itself via an autoregulatory loop mediated by the upstream PrfA-dependent plcA promoter.
We have recently characterized prfA* mutants from L. monocytogenes which, as a result of a single amino acid
substitution in PrfA, Gly145Ser, constitutively overexpress prfA and the genes of the PrfA virulence regulon.
Here, we show that about 10 times more PrfA protein is produced in a prfA* strain than in the wild type. Thus,
the phenotype of prfA* mutants is presumably due to the synthesis of a PrfA protein with higher promoter-
activating activity (PrfA*), which keeps its intracellular levels constantly elevated by positive feedback. We
investigated the interaction of PrfA and PrfA* (Gly145Ser) with target DNA. Gel retardation assays performed
with a DNA fragment carrying the PrfA binding site of the plcA promoter demonstrated that the PrfA* mutant
form is much more efficient than wild-type PrfA at forming specific DNA-protein complexes. In footprinting
experiments, the two purified PrfA forms interacted with the same nucleotides at the target site, although the
minimum amount required for protection was 6 to 7 times lower with PrfA*. These results show that the
primary functional consequence of the Gly145Ser mutation is an increase in the affinity of PrfA for its target
sequence. Interestingly, similar mutations at the equivalent position in CRP result in a transcriptionally active,
CRP* mutant form which binds with high affinity to target DNA in the absence of the activating cofactor,
cAMP. Our observations suggest that the structural similarities between PrfA and CRP are also functionally
relevant and support a model in which the PrfA protein, like CRP, shifts from transcriptionally inactive to
active conformations by interaction with a cofactor.
Virulence genes in the gram-positive, facultative intracellu-
lar pathogen Listeria monocytogenes are regulated by the pleio-
tropic transcriptional activator PrfA, encoded by the prfA gene
(6, 8, 21, 25, 27). An ambient temperature of 37°C is necessary
for the transcriptional activation of prfA and PrfA-dependent
genes (24). This is, however, not sufficient for the full activation
of the PrfA regulon. Wild-type strains express PrfA-regulated
genes to a very low level in rich media (e.g., brain-heart infu-
sion medium [BHI]) at 37°C (30), but strongly activate their
transcription if cultured in BHI treated with activated charcoal
(28–30) or if transferred from BHI to minimal essential me-
dium (5). This requirement for a suitable combination of en-
vironmental signals of a physical and chemical nature may be
a fail-safe mechanism used by L. monocytogenes to prevent the
expression of virulence genes in situations in which they are
not required, i.e., when the bacteria are outside an appropriate
host niche. Recent observations have suggested that there is
also a mechanism of negative regulation in L. monocytogenes
which abolishes the expression of virulence genes in the pres-
ence of readily fermentable carbon sources, such as glucose or
cellobiose (26, 28). The molecular basis and biological rele-
vance of this repression mechanism are unknown.
The primary structure of PrfA has significant similarities to
that of Escherichia coli cyclic AMP (cAMP) receptor protein
(CRP) and other members of the CRP-FNR family of bacterial
transcription factors (21, 23). PrfA has, for example, a helix-
turn-helix (HTH) motif in the C-terminal region, at the same
position as in CRP and related proteins. This HTH motif has
been shown to interact specifically with target DNA sequences
called “PrfA-boxes,” which are 14-bp-long palindromes cen-
tered at position 241 relative to the transcription start site in
PrfA-dependent promoters (3, 9, 11, 33). Binding to these
PrfA-boxes is affected by the number of nucleotide mismatches
they carry, becoming weaker as the sequence diverges from the
perfect palindrome (4, 12, 34). The symmetrical structure of
PrfA-boxes suggests that like CRP, PrfA binds to target DNA
as a dimer, and there is experimental evidence that PrfA forms
a homodimer in solution (9).
Evidence that PrfA and CRP are functionally related has
been provided by our recent characterization of prfA* mutants
from L. monocytogenes (28, 29, 31). Mutatis mutandis, these
prfA* strains are analogous to the crp* mutants of E. coli in
that they constitutively overexpress prfA and PrfA-dependent
genes under culture conditions in which the PrfA regulon is
normally downregulated (e.g., at 37°C in BHI), to levels
* Corresponding author. Mailing address: Unidad de Microbiologı´a
e Inmunologı´a, Facultad de Veterinaria, Universidad Complutense,
28040 Madrid, Spain. Phone: 34-91-394-3704. Fax: 34-91-394-3908.
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reached by wild-type strains only if cultured in charcoal-treated
BHI (28–30). These prfA* mutants carry a Gly3Ser substitu-
tion in residue 145 of PrfA that seems to increase the tran-
scriptional activity of the regulator, releasing it from a variety
of repressor signals including low temperature and growth on
glucose or cellobiose (28–30). This mutation is located in a
PrfA region of 11 amino acids (residues 141 to 151) with a
sequence very similar (70% similarity) to that of the D a-helix
of CRP (29). Several crp* mutations in E. coli that allow CRP
to function in the absence of cAMP, the cofactor required for
its allosteric activation, also map in this region (13, 15a, 20).
One such CRP* mutation, Ala144Thr, which presumably mim-
ics the conformational change caused by the cofactor (19, 20),
maps in the aligned proteins to the position equivalent to that
of the Gly3Ser PrfA mutation (29). These observations led us
to hypothesize that PrfA functions via a cofactor-mediated
allosteric transition mechanism similar to that of CRP, and
that the Gly145Ser mutation is a cofactor-independent PrfA*
form that is “frozen” in an active conformation (29).
In this study, we investigated the interaction of wild-type
PrfA and mutant PrfA* (Gly145Ser) with target DNA. As for
CRP* altered forms (2, 32, 35), the Gly145Ser mutant protein
bound with higher affinity to specific DNA than did the wild-
type protein, further supporting the notion that PrfA is a struc-
tural and functional homolog of CRP.
MATERIALS AND METHODS
L. monocytogenes strains and culture conditions. P14, an L. monocytogenes
wild-type strain of serovar 4b, and its prfA* mutant, P14-A, have been described
in detail elsewhere (28–31). L. monocytogenes EGD, a wild-type strain of serovar
1/2a, and its prfA deletion mutant, DprfA, have also been previously described (3,
5, 29). They were grown in BHI broth at 37°C with shaking.
General DNA techniques. Restriction enzymes were purchased from Pharma-
cia and used as recommended by the manufacturer. The Expand high-fidelity
PCR system (Boehringer Mannheim) was used to amplify specific DNA frag-
ments. PCR products were purified from gels with the Qiaquick (Qiagen) gel
extraction kit. Plasmid DNA was extracted from E. coli with a plasmid purifica-
tion kit from Qiagen. DNA sequencing was performed with an Applied Biosys-
tems 377 apparatus.
L. monocytogenes cell protein extracts, SDS-PAGE, and anti-PrfA immuno-
blotting. Soluble protein extracts from L. monocytogenes were prepared and
stored as described by Bo¨ckmann et al. (3). Total protein concentration was
determined with the Bio-Rad Protein-Microassay. Sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) was performed with 12% acryl-
amide slab gels as described by Laemmli (22). For immunoblotting, proteins
were electrotransferred from the gels to nitrocellulose sheets (Schleicher &
Schuell), and PrfA was detected by using a previously described anti-PrfA poly-
clonal hyperimmune serum (3), peroxidase-conjugated secondary antibodies,
and 4-chloro-1-naphthol.
Expression in E. coli and purification of wild-type and Gly145Ser mutant PrfA
proteins. The prfA and prfA* alleles from P14 and P14-A, respectively, were
amplified by PCR with the oligonucleotide pair N-PR1 (59-ATGACTCGAGA
ACGCTCAAGCAGAAGAA-39) and C-PR1 (59-CTGTAGATCTTTTAATTT
AATTTTCCCCA-39), which contain XhoI (N-PR1) and BglII (C-PR1) restric-
tion sites (underlined). The resulting prfA-containing DNA fragments were
cloned in E. coli with the pMOSBlue T-vector kit (Amersham), and then trans-
ferred to pFLAG-MAC expression vector (Sigma) by using the XhoI and BglII
sites, giving rise to the plasmids pF-PrfA and pF-PrfA*(G145S). A fusion was
created in these plasmids, resulting in a sequence that encodes a recombinant
PrfA protein with an N-terminal tag of 14 amino acids including an 8-mer
peptide marker (FLAG epitope). The whole open reading frame was checked by
sequencing both strands in each expression plasmid. Recombinant PrfAs were
overproduced in E. coli DH5a. Host bacteria were grown at 37°C in 500 ml of
Luria-Bertani medium containing ampicillin (50 mg/ml) until the optical density
at 600 nm was 1.0, and expression was induced by adding 1 mM IPTG (isopropyl-
b-D-thiogalactopyranoside). After 3 h, the induced bacteria were pelleted and
lysed by suspension in 20 ml of lysis buffer A (50 mM Tris-HCl [pH 8], 5 mM
EDTA, 50 mg of sodium azide per ml, 0.25 mg of lysozyme per ml) and addition
of 2 ml of lysis buffer B (1.5 M NaCl, 100 mM CaCl2, 100 mM MgCl2, 0.02 mg
of DNase I per ml, 50 mg of phenylmethylsulfonyl fluoride). Recombinant PrfAs,
which did not form inclusion bodies in E. coli, were purified from the bacterial
soluble extract by column affinity chromatography with anti-FLAG M2 mono-
clonal antibody resin (Sigma), according to the manufacturer’s instructions. The
eluted fractions were analyzed by SDS-PAGE with Coomassie blue staining. The
fractions containing .98% pure PrfA (which migrated as a band of 28.5 kDa, 1.5
kDa larger than predicted from the prfA sequence due to the presence of the
extra 14 N-terminal amino acids) were collected, concentrated by Centricon
devices (Amicon), and preserved at 220°C with 20% glycerol.
DNA mobility shift and footprinting assays. A 136-bp double-stranded PCR
fragment containing the plcA-hly promoter region was used as target DNA. It
was amplified from strain P14 with primers YV3 (59-TCCTATCTAGAAGTTA
CTTTTATGTC-39) and YV4 (59-TATTGGATCCATTCGCTTCTAAAGATG-
39), which contain XbaI and BamHI restriction sites (underlined). Previously
described protocols were used for electrophoretic mobility shift assays with L.
monocytogenes protein extracts or purified PrfA proteins (3). DNase I footprint-
ing experiments were performed as previously described (9).
RESULTS
Amounts of PrfA in the wild-type and the prfA* (Gly145Ser)
mutant of L. monocytogenes. The levels of expression of prfA
are primarily controlled by the PrfA-dependent plcA promoter,
from which a bicistronic transcript covering the plcA-prfA
operon is generated. This plcA-prfA mRNA creates an auto-
regulatory loop that is essential for the normal function of the
PrfA regulon, presumably because it ensures the synthesis of
sufficient quantities of the PrfA protein (5, 7, 12, 24, 25, 29)
(see Fig. 6). Even if the prfA gene remains intact, any inter-
ruption of this autoregulatory loop (e.g., by insertional mu-
tagenesis in plcA or in the plcA-prfA intergenic region) leads to
a PrfA2 phenotype (7, 11, 25, 28, 29). trans-complementation
experiments have suggested that the mutant form of PrfA
synthesized from prfA* (Gly145Ser), PrfA*, is more effective
than the wild-type protein at activating PrfA-dependent pro-
moters (28, 29). This would result in PrfA* constantly switch-
ing on the autoregulatory loop such that more PrfA protein
was produced in the mutant prfA* background than in the wild
type. We tested this by analyzing cell extracts of the L. mono-
cytogenes wild-type strain, P14, and its prfA* mutant, P14-A,
grown in BHI at 37°C, by Western blotting with anti-PrfA
antibodies.
There was clearly more PrfA protein in P14-A than in P14
(Fig. 1), suggesting that PrfA* did indeed activate its own
synthesis by a positive feedback mechanism. The constitutive
overexpression of PrfA-dependent virulence genes in prfA*
mutants is therefore presumably due to the sustained produc-
tion of high levels of a transcriptionally active PrfA* form.
Densitometric analysis of the blots showed that the intracellu-
lar levels of PrfA* were around 10 times higher in P14-A than
in P14.
DNA-protein complex formation by PrfA and PrfA*
(Gly145Ser) in cell extracts of L. monocytogenes. We investi-
gated whether the differences in virulence gene transcription in
the wild type and prfA* mutants (29, 30) were due to differ-
ences in the DNA-binding activity of the corresponding PrfA
and PrfA* proteins. Electrophoretic mobility shift assays were
carried out with cell extracts from P14 and P14-A and a 136-bp
PCR fragment containing the plcA promoter and its PrfA-box,
FIG. 1. Determination of PrfA protein in L. monocytogenes P14 (wild type),
P14-A (prfA* [Gly145Ser] mutant from P14), and EGD (control wild-type
strain). Total cell extracts from these strains were subjected to SDS-PAGE in a
12% acrylamide gel (protein amounts loaded: P14 and EGD, 30 mg; P14-A [from
left to right], 30, 15, 10, 5, and 2.5 mg) and analyzed by Western immunoblotting
with an anti-PrfA hyperimmune serum. The PrfA protein is detected as a 27-kDa
band. Note that equivalent amounts of PrfA protein are present in 30 mg of the
P14 and EGD extracts and 2.5 mg of the P14-A extract.
6656 VEGA ET AL. J. BACTERIOL.
 o
n
 February 20, 2014 by guest
http://jb.asm.org/
D
ow
nloaded from
 
used as the target DNA. This PrfA-box is shared with the
divergently transcribed hly gene and represents the “perfect”
palindrome, to which PrfA presumably binds with maximal
affinity (4, 34). Extracts from L. monocytogenes EGD, a wild-
type strain in which the deduced amino acid sequence of PrfA
is identical to that of P14 (29), and its prfA deletion mutant
(EGD DprfA) were used as controls.
Specific protein-DNA complexes (CI) (3, 9) were formed
with the cell extracts from all of the PrfA-proficient strains
used (Fig. 2). However, there was a higher level of complex
formation with the PrfA*-containing extract than with that
containing wild-type PrfA, as determined from the intensities
of the CI PrfA-dependent complexes formed (see lanes b and
h, in which the amounts of PrfA protein are equivalent). The
level of PrfA-dependent complex formation with extracts from
EGD was identical to and as low as that with the extract from
the P14 wild-type strain (lanes a and c). As expected, there was
no binding activity observed with the EGD DprfA extract (lane
d). Therefore, the higher transcriptional activity of the PrfA*
(Gly145Ser) mutant form correlates with a higher affinity for
target DNA.
Interaction of purified PrfA and PrfA* (Gly145Ser) with
target DNA. We characterized the differential interaction of
PrfA and PrfA* (Gly145Ser) with the target DNA in more
detail by gel retardation assays with the purified proteins. The
PrfA proteins from strains P14 and P14-A were produced in E.
coli with a FLAG epitope fused to the N terminus, which
allowed them to be purified by affinity chromatography with an
anti-FLAG-peptide monoclonal antibody (see Materials and
Methods). The recombinant purified proteins were called F-
PrfA and F-PrfA*, respectively. Addition of an N-terminal tag
to PrfA has been shown to have no major effect on the DNA-
binding function of the protein (3, 9). We used a recently
described protocol with which direct, specific binding of puri-
fied PrfA can be observed in the absence of additional factors
from the listerial cytoplasm (9). In this case, a high-mobility
DNA-PrfA complex (CIII) is formed (9).
As little as 1.5 ng of F-PrfA* was sufficient to produce a
visible CIII complex with the 136-bp DNA fragment containing
the plcA-hly PrfA-box (Fig. 3). This interaction was specific, as
shown by the ability of the unlabeled specific probe and the
inability of nonspecific DNA to compete out CIII complex
formation (Fig. 4). In contrast, no mobility shift was detectable
with F-PrfA, even at high protein concentrations (Fig. 3). Ad-
dition of PrfA-free L. monocytogenes extract (from EGD
DprfA) led to CI complex formation by F-PrfA* and, also, by
F-PrfA (Fig. 3). Therefore, although it cannot directly interact
with DNA to form a visible CIII complex, purified wild-type
PrfA is able to bind to its target site in the presence of addi-
tional factors from the listerial extract. These results show that
the PrfA* form is clearly more efficient than the wild-type
protein at establishing direct interaction with the PrfA-specific
target site.
We investigated whether the higher DNA-binding activity of
PrfA* was associated with a different pattern of interaction at
FIG. 2. Electrophoretic mobility shift assays with a 136-bp DNA fragment
containing the PrfA-box of the plcA-hly promoter region and L. monocytogenes
cell extracts. Lanes: a and b, P14 (30 and 60 mg, respectively); c, EGD (30 mg);
d, DprfA mutant from EGD (30 mg); e to h, P14-A (30, 15, 10, and 5 mg,
respectively). Lanes b and h contain equal amounts of PrfA protein (Fig. 1). CI
and CIII, respectively, low- and high-mobility specific PrfA-DNA complexes.
(See text and references 3 and 9 for details.)
FIG. 3. Binding of the purified PrfA proteins to the plcA-hly promoter frag-
ment. Various amounts of PrfA preparation were used (from left to right: PrfA*
[Gly145Ser], 0.5, 1.5, 3, 6, and 18 ng; PrfA, 120, 240, and 480 ng). Lanes a and
b: low-mobility CI-specific protein-DNA complex formation by purified PrfA*
and PrfA proteins (50 ng each), respectively, in the presence of a PrfA-free L.
monocytogenes cell extract (30 mg) from EGD DprfA. CIII, high-mobility specific
PrfA-DNA complexes. (See text and references 3 and 9 for details.)
FIG. 4. Specificity of the interaction of PrfA* (8 ng) with target DNA result-
ing in CIII complex formation. Competition assays with (from left to right) 50-,
100-, 200-, and 400-fold molar excess of specific (unlabeled 136-bp plcA-hly
promoter fragment) and nonspecific DNA (from herring sperm). Lanes: a, con-
trol with the labeled 136-bp plcA-hly promoter fragment alone; b, control with
the labeled probe plus 8 ng of purified PrfA*.
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the PrfA site by footprinting analysis of the DNA sequence
protected by F-PrfA and F-PrfA* in the plcA-hly promoter
region (Fig. 5). Various amounts of the purified PrfAs were
used to further evaluate the differential binding affinity of the
two proteins for the target site. In contrast to the results ob-
tained with gel retardation assays, we did detect direct inter-
action of F-PrfA with target DNA. This probably results from
the different experimental conditions for the two techniques,
particularly the relatively high concentration of poly(dI-dC),
used in the mobility shift experiments as nonspecific compet-
itor to minimize nonspecific or low-affinity protein-DNA inter-
actions (9). However, the amount of purified wild-type protein
required for complete protection was significantly higher (6 to
7 times) than that for F-PrfA*. The DNA region protected
from DNase I digestion was exactly the same for both purified
proteins (positions 258 to 233 relative to the transcriptional
start site of hly, including the PrfA-box palindrome and 10 bp
upstream and 2 bp downstream from it) (Fig. 5) and was
concordant with that previously reported for PrfA (9).
DISCUSSION
We have shown, by electrophoretic mobility shift and foot-
printing assays, that (i) wild-type PrfA interacts weakly with
the specific target DNA, and (ii) a mutant PrfA form, PrfA*
(Gly145Ser), has a much higher DNA-binding activity than the
wild-type protein. There was no difference between the DNA
sequences footprinted by the mutant and wild-type PrfA pro-
teins, demonstrating that the primary functional consequence
of the Gly145Ser substitution is a very significant increase in
binding affinity for the target DNA. Since prfA is positively
regulated by its own product, PrfA (24, 25, 28, 29) (Fig. 6), the
expected outcome of the mutation in vivo is an increase in the
levels of the PrfA protein. This has been also demonstrated
herein. Our results are consistent with the physiological prop-
erties of wild-type and prfA* (Gly145Ser) backgrounds of L.
monocytogenes, which in normal culture media express low and
constitutively high levels of PrfA-dependent genes, respec-
tively (28–30).
PrfA and CRP exhibit significant similarities at the level of
primary structure (21, 23, 33). The observations here reported
with PrfA are also very similar to those for the structure-
function relationships of CRP, supporting the notion that PrfA
acts via a regulatory mechanism similar to that of the E. coli
transcription factor. The inactive form of CRP binds to specific
DNA with very low affinity, so the interaction is not normally
detectable in gel retardation assays. However, if complexed
with the activating cofactor, cAMP, CRP undergoes a confor-
mational change that is associated with a dramatic increase in
affinity for the target DNA (2, 16, 17, 35). Binding of the
cofactor is thought to alter intersubunit alignment and inter-
domain orientation in CRP, ultimately resulting in the protru-
sion of the F a-helix which is part of the HTH DNA-binding
motif, thereby facilitating productive specific protein-DNA in-
teraction (1, 14, 16, 19, 20). CRP* mutations in the D a-helix,
which spans residues 139 to 150, close to the hinge region
connecting the N-terminal cAMP-binding domain and the C-
terminal DNA-binding domain of the CRP subunit (13, 15a),
are thought to evoke the conformational change caused by
cAMP, resulting in transcriptional activation in the absence of
significant amounts of the cofactor (14, 19, 20, 32). In this D
a-helix, any amino acid substitution introducing a larger side
chain at position 144, which aligns with PrfA residue 145 (the
site of our PrfA* mutation) (29), results in a cAMP-indepen-
dent CRP* phenotype (19). According to the determined crys-
tal structure of CRP, amino acid 144 faces residue 190 in the F
a-helix (20, 37). Therefore, the cAMP-independent phenotype
is presumably due to the larger side chain pushing the DNA-
binding sequence outward (19, 20). The PrfA* mutation stud-
ied, mapping to a region that is remarkably homologous to the
D a-helix of CRP (29), is similar to the CRP* mutation pre-
viously characterized at position 144, Ala to Thr (14, 15a, 20),
and involves the replacement of a small amino acid (Gly) with
a larger one (Ser). A second CRP* mutation described at
position 141 in the D a-helix is also a Gly3Ser substitution,
and we recently characterized another PrfA* mutation that
maps nearby within the same D a-helix-homologous region,
which also involves a replacement by a bulkier amino acid (36).
Except for the fact that PrfA has an extra 25 amino acids at the
extreme C terminus, the C-terminal domain of CRP is very
similar (45% identity, 60% similarity from amino acid 128 to
amino acid 201) to the corresponding region in PrfA (21, 23,
36). These observations suggest that the mutations resulting in
the PrfA* phenotype are associated with conformational
changes in the DNA-binding domain similar to those that are
thought to occur in CRP* mutant proteins.
Our findings provide support for our model of PrfA-depen-
dent regulation (29). In this model, similar to that proposed for
CRP, PrfA undergoes an allosteric transition from an inactive
to an active conformation upon interaction with an environ-
mentally regulated low-molecular-weight cofactor. A key ele-
ment of this model is the positive autoregulatory circuit of
prfA, an aspect in which the listerial regulatory gene also re-
sembles the transcriptional control mediated by crp in E. coli
(15). (See Fig. 6 for a detailed description of the model.)
Two typical features of CRP are particularly well conserved
in PrfA. One is the HTH motif in the C-terminal region, for
which the functional similarity between the two proteins has
been already documented (33). The other is a series of short
FIG. 5. DNA footprinting experiments with various amounts of the purified
PrfA proteins (PrfA*, 0, 0.5, 1.5, 3, 6, and 18 ng; PrfA, 10, 20, 40, and 120 ng) and
the plcA-hly promoter fragment. The protected sequences, identical for the two
PrfA proteins, are indicated on the right. The palindromic PrfA binding site is
boxed, and numbers indicate the nucleotide position with respect to the tran-
scription start site of the hly mRNA. The hypersensitive nucleotide (A) at
position 240, close to the center of the palindrome, is in boldface. To the left is
shown the uncleaved probe.
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antiparallel b-strands delimited by glycine residues, which may
form a b-roll structure involving most of the N-terminal half of
the protein (21, 23). The prediction of such a structure in PrfA
is quite intriguing, because in CRP it forms the pocket in which
the activating cofactor, cAMP, is buried in the N-terminal
domain of the protein (20). However, cAMP is undetectable,
and it is not known to function as an effector molecule in
gram-positive bacteria (18). In fact, most of the residues in
CRP that are important for cAMP binding are not conserved
in PrfA (21, 36), and addition of exogenous cAMP does not
result in PrfA activation (36). It is, however, unknown whether
cAMP is taken up by Listeria. Preliminary studies with the
extrinsic fluorescence probe 8-anilino-1-naphthalenesulfonic
acid (ANS) have shown that as for CRP (16), the addition of
cAMP to purified PrfA results in a significant fluorescence
quenching (36). This indicates that cAMP induces a confor-
mational change, but not necessarily that it allosterically acti-
vates PrfA. The cyclic nucleotide cGMP, for example, does not
functionally activate CRP, but it does bind to it with an affinity
similar to that of cAMP, and there are cAMP analogs that bind
to CRP and cause a conformational change similar to that
elicited by cAMP but do not activate transcriptional function
(10). It is therefore possible that the putative cofactor for PrfA
is a cyclic nucleotide similar to cAMP. We are currently work-
ing toward the identification of this putative PrfA cofactor and
the genetic characterization of the signal transduction machin-
ery that connects the PrfA system with the extracellular envi-
ronment.
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